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ABSTRACT 
INTRODUCTION:  Meperidine is a synthetic opioid analog that is fFequently pre- 
scribed for acute pain management. Normeperidine, the only active metabolite of me- 
peridine, is neurotoxic and can cause significant central nervous ystem adverse vents. 
CASE SUMMARY:  A 29-year-old woman (height, 170 cm; weight, 85 kg) pre- 
sented to Marmara University Hospital Emergency Department, Istanbul, Turkey, com- 
plaining of low back pain she described as "stabbing." Physical examination revealed 
impaired lower-extremity mobility and normal vital-sign findings. There was no evi- 
dence of foot drop, head or other trauma, and systemic physical examination was unre- 
markable. Other common causes (eg, pyelonephritis, nephrolithiasis, pancreatitis, 
tramna) of lower back pain were excluded. To achieve analgesia, meperidine 80 mg was 
administered intravenously in 100 mL of isotonic saline solution for 20 minutes. With- 
in 20 minutes, analgesia was achieved, but the patient developed retrograde amnesia, 
becoming disoriented to time, location, and persons. Her speech slowed and percep- 
tional changes developed. After the onset of amnesia, a complem physical examination was 
conducted. It Failed to reveal focal neurologic deficit, and laboratory (sodium, potassium, 
magnesimn, phosphorus, erum creatinine, blood urea nitrogen, albmnin, bilirubin, 
hemoglobin, and platelet coun0 and subsequent vital-sign findings (blood pressure, 
150/100 mm Hg; heart rate, 100 beats per minute; respiratory rate, 18 breaths per 
minute; body temperature, 37°C; and pulse oximetry, 99%,) were within the normal 
range. Noncontrast computed tomography did not reveal any abnormality. Initially, 
the patient's condition was attributed to medication error due to incorrect dosage or 
infusion rate. Despite a review of medication logs, equipment, and the vital-sign 
record, the etiology for the phenomenon could not be identified. Meperidine was 
discontinued and oxygen and intravenous i otonic saline solution were initiated as 
supportive treatment. Three hours after meperidine administration was discontinued, 
the amnesia nd disorientation spontaneously resoDed. 
CONCLUSION:  Meperidine was probably associated with reversible amnesia in 
this healthy patient after a single therapeutic dose. (~'Nff The# Res C/'],*I E~. 2008;69: 
159 163) © 2008 Excerpta Medica Inc. 
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INTRODUCTION 
Meperidine is a synthetic opioid analog that is frequently prescribed for acute pain 
management. I s narcotic analgesic effects are qualitatively similar to those of mor- 
phine. The most prominent of these involve the central nervous system and organs 
composed of smooth nmscle. 1 The principal actions of therapeutic value are analgesia 
and sedation. 1 Compared with morphine, meperidine has a reported slightly faster onset 
of action (10 60 vs 20-60 minutes), a shorter duration of action (2.5 3.5 vs 4-5 hours), 
and shorter tl/2 (2.5 4 vs 4-5 hours). 2However, meperidine has the narrowest therapeu- 
tic index of all the opioids. 2Acting predominantly asa p-receptor agonist, meperidine 
produces its analgesic effects similar to that of morphine. In addition, meperidine has 
many of the same adverse vents (AEs) as morphine, including respiratory depression, 
sedation, and constipation. 2 Meperidine is most often administered parenterally. It is 
metabolized by the liver into 2 metabolites: meperidinic acid (inactive) and normeperi- 
dine (active), which are excreted renally. 3
Meperidine has been reported to be associated with neurotoxicity, a potentially severe 
AE that is due to the accumulation of the metabolite normeperidine. 4 It is difficult to 
predict which individuals will experience neurotoxic effects and how severe the reaction 
will be. 4 Normeperidine-mediated n urotoxicities (eg, nervousness, agitmion, hyper- 
reflexia, myoclonus, tremors, seizures, delirium, hallucinations, reversible parkinsonism) 5 
are more likely to occur with higher doses, extended treatment, 6 or renal impairment. 
However, some of these symptoms can occur in healthy patients after a single dose / 
Retfogfa~e a~lJle.~ia is defined as a clinical condition in which an individual is unable 
to recall events that occurred prior to the onset of memory loss. s In its pure form, it 
typically results from injury to regions of the brain that are closely associated with 
episodic and/or declarative memory. Amnesia has several root causes, most of which are 
traceable to brain injury related to physical trauma, disease, infection, drug or alcohol 
abuse, or reduced blood flow to the brain (vascular insufficiency), s 
The aim of this article was to report a case of reversible retrograde amnesia in a 
healthy patient who was administered IV meperidine for low back pain. 
CASE SUMMARY 
A 29-year-old woman (height, 170 cm; weight, 85 kg) presented to Marmara University 
Hospital's Emergency Department, Istanbul, Turkey, complaining of low back pain she 
described as "stabbing." Physical examination revealed impaired lower extremity mobility 
and normal vital-sign findings (blood pressure, 130/85 mm Hg; heart rate, 90 beats per 
minute (bpm); respiratory rate, 18 breaths per minute; body temperature 37.2°C; and 
pulse oximetry [SpO2] , 99 mm Hg). There was no evidence of foot drop, head or other 
trauma, and systemic ptlysical examination was unremarkable. Other common causes (eg, 
pyeloneptlritis, nephrolithiasis, pancreatitis, trauma) of lower back pain were excluded. 
Muscle spasm was identified in the lumbar region. The patient's medical history 
revealed a lumbar disc hernia that had been diagnosed 2 years prior and medical treat- 
ment was recommended. The patient's family medical history was unremarkable, and 
she was not receiving any medication. According to the patient, she had no known aller- 
gies and had not ingested any alcohol. 
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To achieve analgesia t a fast onset of action, meperidine (Pethidine ®, Antigen 
Pharmaceuticals Ltd., Tipperary, Ireland) 80 mg was administered intravenously in
100 mL of isotonic saline solution for 20 minutes. Within 20 minutes, analgesia was 
achieved, but the patient developed retrograde amnesia, becoming disoriented to time, 
location, and persons. Her speech sbwed and perceptional changes developed. She did 
not know the date, her location, or why she was present, nor could she identif?~ her 
husband. Although we did not test the patient's memory prior to the administration of
meperidine, she had been responding well in terms of answering questions and speak- 
ing coherently. After the onset of amnesia, a complete physical examination was con- 
ducted. The subsequent physical examination failed to reveal focal neurologic deficit, 
and laboratory (sodium, potassium, magnesium, phosphorus, erum creatinine, blood 
urea nitrogen, albumin, bilirubin, hemoglobin, arid platelet count) and subsequent 
vital-sign findings (blood pressure, 150/100 mm Hg; heart rate, 100 bpm; respiratory 
rate, 18 breaths per minute; body temperature, 37°C; and SpO2, 99%) were within the 
normal range. Noncontrast computed tomography did not reveal a W abnormality. 
Initially, her condition was attributed to medication error due to incorrect dosage 
or infusion rate. Medication logs were confirmed, equipment rechecked, and the 
vital-sign record was reviewed. However, the etiology for the phenomenon could not 
be identified. The patient was questioned again regarding use of medications, including 
opiates and herbal products; all were denied. The patient's responses were confirmed 
by her husband. 
Meperidine was discontinued and oxygen and intravenous i otonic saline solution 
were initiated as supportive treatment. A neurologic onsultation was performed, and 
the neurologist recommended monitoring the patient in the emergency department. 
Three hours after meperidine administration was discontinued, am nesia and disorienta- 
tion spontaneously resolved. The patient's condition was theref()re attributed to meper- 
idine. The patient was observed for >4 hours and was then discharged. 
DISCUSSION 
According to the V/orld ttealth Organization 9 an adverse dr~g feclcTioJ~ is "a noxious, 
unintended response to a drug that occurs at doses normally used in humans for pro- 
phylaxis, diagnosis, or therapy or for modification of physiologic function. "9 
Our patient developed retrograde amnesia after meperidine administration. The 
duration of amnesia (3 hours) and the half-life of meperidine (2.5 4 hours) were consis- 
tent. Normeperidine is primarily eliminated renally, and the half-life (13 30 hours) is 
5 to 10 times longer than that of meperidine, depending on renal function. We could 
not identify any other explanation for amnesia in our patient. Risks for neurotoxicity 
include high, frequent doses (>150 mg TID or OID), l° coadministration f agents that 
may induce seizures or lower the seizure threshold, and renal dysfunction. 1 In our 
patient, there was no reported use of other medications and all hepatic and renal func- 
tions were within the normal range. 
Meperidine is not recommended as a first-line opioid analgesic. 5,6,11 The drug is 
lipophilic, and it has a more rapid onset and shorter duration of analgesia (usually 
2.5 3.3 hours) than other short-acting opioids. This feature might be overlooked when 
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it is prescribed at a 4- to 6-hour dosing interval, which results in uncontrolled pain 
before the next dose is due. 5,11 Meperidine is believed to be effective in the management 
of pain due to pancreatitis, biliary and renal colic, back injury, and migraine. No studies 
have found that meperidine is more effective than morphine, le
To identify instances of AEs associated with meperidine, we performed a literature 
search in MEDLINE for relevant English-language publications from 1990 to June 
2007 using key terms meper}dgle, amnesia, opioid a~la/gesi~; and ce~ltra/ nervous ystem tox#ity. 
We did not identify any reports of AEs associated with meperidine and amnesia. ~e  
also reviewed the US Food and Drug Administration's (FDA) prescribing information 
and the FDA's Adverse Event Reporting System 1 from January 1990 through June 
2007. We also contacted the company that distributes meperidine (Filiz Ilac, Ltd., 
Ankara, Turkey). They indicated that they were not aware of any evidence suggesting 
an association between meperidine and amnesia. The incident was reported to the 
Turkish Ministry of Health 13 (Ankara, Turkey). 
The Naranjo Adverse Drug Reaction probability scale 14 was used as an objective 
measure of causality. A score of 6 indicated that meperidine was the probable cause of 
amnesia in this patient. 
CONCLUSION 
Meperidine was probably associated with reversible retrograde amnesia in this healthy 
patient afler a single therapeutic dose. 
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